Naratriptan Sandoz

Naratriptan, the active ingredient in Naratriptan Sandoz, is a selective serotonin (5‑HT1) receptor agonist presented as an oral dosage form for oral use. It is used for the acute treatment of migraine attacks in adults. GNH USA supplies Naratriptan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is indicated for the acute management of migraine. - Migraine: provides rapid relief of headache and associated symptoms during an attack. - Migraine with aura: reduces severity of headache and visual disturbances. - Migraine without aura: alleviates pain and nausea associated with the attack.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired after dosing. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Chest pain: may indicate cardiac ischemia and requires immediate medical attention. - Severe hypertension: sudden increase in blood pressure that can be dangerous. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents.

Before prescribing Naratriptan, clinicians should consider several safety aspects. - Cardiovascular disease: avoid use in patients with uncontrolled heart conditions. - History of stroke or transient ischemic attack: contraindicated due to vasoconstrictive effects. - Concomitant ergotamine or other triptans: increase risk of vasospasm, should not be combined. - Pregnancy: only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review all serotonergic medications to minimize serotonin syndrome risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Naratriptan may interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Ergotamine derivatives: combined use can cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects may be hazardous.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: monitor for signs of serotonin syndrome. - Beta‑blockers: may affect blood pressure response. - Antihypertensive agents: monitor blood pressure for additive effects.